New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

On November 6, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology platform, reported new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data demonstrate potent EVX-01 induced immune responses and further underline the strong predictive performance of Evaxion’s AI-Immunology platform. It will be presented in both an oral and a poster session today and tomorrow respectively at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting, taking place in Phoenix, Arizona.

"It is exciting to announce yet another set of new and promising data providing insights into the magnitude, quality and systemic impact of EVX-01-induced immunity in advanced melanoma. The data provide a clear demonstration of the very strong immune responses induced by EVX-01 and also validates our AI-Immunology platform further. We are looking forward to sharing and discussing this data with both scientific stakeholders and potential business partners at the important SITC (Free SITC Whitepaper) meeting", says Birgitte Rønø, CSO and COO of Evaxion.

Comprehensive data package
The new data adds to EVX-01’s already comprehensive data package which includes three-year clinical response and immune data presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 held in October. These data showed 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in the phase 2 trial.

New findings include detection of EVX-01 induced neoantigen-specific T-cells directly ex vivo, which is a clear testament to the magnitude of the vaccine-induced immune responses. Ex vivo responses were dominated by CD4+ T-cells, while CD8+ T-cell responses were observed in half of patients.

The data also documents a significant association (p<0.001) between predictions by AI-Immunology and actual T-cell responses, confirming the strong predictive performance of the platform. Essentially, the platform predicts, with very high precision, which neoantigens will illicit the strongest immune responses allowing for selection of these as optimal vaccine targets.

SITC oral and poster presentation details:

Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
Abstract#: 502
Oral presentation:

Session: 105b: Rapid Oral – Clinical 1
Location: Phoenix Convention Center, West Building-300 Level – 301BC
Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20.30-21.30 CET
Presenter: Mads Lausen, Senior Scientist at Evaxion
Poster presentation:

Session: Poster Session
Location: Phoenix Convention Center, North Building-Lower Level – Exhibition Halls 4-6
Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
Presenter: Mads Lausen, Senior Scientist at Evaxion
About the phase 2 trial
The phase 2 trial investigated EVX-01 in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial received a unique vaccine designed with Evaxion’s AI-Immunology prediction platform and manufactured based on their individual biology.

At two-year follow-up, the trial demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Clinical and T-cell responses were sustained at three-year follow-up. 89% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab). In the third year, a subset of patients received EVX-01 as stand-alone therapy. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system by mounting a targeted response against tumor-specific neoantigens.

(Press release, Evaxion, NOV 6, 2026, View Source [SID1234674390])

Xspray Pharma publishes Interim Report for the third quarter 2026

On November 6, 2026 Xspray Pharma reported Interim results for the third quarter 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

July–September 2026, Group

Net sales amounted to SEK 0 thousand (0)
Earnings before tax amounted to SEK -39,323 thousand (-47,332)
Earnings per share before dilution amounted to SEK -0.83 (-1.25)
Cash flow from operating activities amounted to SEK -33,374 thousand (-41,354)
Cash flow from investing activities amounted to SEK -5,616 thousand (-6,865)
January–September 2026, Group

Net sales amounted to SEK 0 thousand (0)
Earnings before tax amounted to SEK -114,497 thousand (-134,537)
Earnings per share before dilution amounted to SEK -2.54 (-3.60)
Cash flow from operating activities amounted to SEK -100,996 thousand (-151,793)
Cash flow from investing activities amounted to SEK -16,990 thousand (-27,698)
Amounts in parentheses refer to the year-earlier period.

Significant events during the quarter

In August, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Xspray Pharma’s New Drug Application (NDA) for Dasynoc. The CRL relates to the previously communicated GMP observations at the third-party manufacturer NerPharMa, as well as a request for additional commercial scale consecutive batch data following already implemented corrective actions. The FDA did not raise questions regarding the clinical data, bioequivalence or stability of Dasynoc, and the risk of medication error raised in previous CRLs has been resolved. Xspray Pharma intends to resubmit the application during Q4 2026 after which a new PDUFA date will be issued.
In September, Xspray Pharma announced that data for Dasynoc and Nilopki had been accepted for poster presentation at the ESH-iCMLf 28th Annual John Goldman Conference on Chronic Myeloid Leukemia in Gothenburg on October 2–4, 2026. The data show significantly more consistent drug exposure with Dasynoc and a significantly lower food effect with Nilopki strengthening their clinical differentiation.
Significant events after the quarter

In October, Xspray Pharma announced that the FDA has confirmed that the NDA for Dasynoc can be resubmitted independently of NerPharMa’s cGMP status, as was previously confirmed for Nilopki. The company maintains its plan to resubmit both applications during Q4 2026, and manufacturing of the required additional commercial batches has commenced. Final regulatory clearance of the facility is still required before approval.
On 5 November, Xspray was informed that the FDA had initiated an unannounced follow-up inspection at NerPharMa’s manufacturing facility, relating to previously identified cGMP-observations.
After the period, the company announced that the Board had decided to carry out a rights issue of shares of approximately SEK 90 million, with preferential rights for the company’s existing owners. The rights issue can be increased by up to SEK 72 million through an over-allotment option. The company has also entered into an agreement with the lender to extend the maturity of its existing loan to 15 August 2028 and, following a contractual repayment, reduce the loan facility to SEK 50 million. The warrants held by the lender, which were issued in spring 2026, will be cancelled and replaced with newly issued warrants in connection with the loan extension.
A message from the CEO
The third quarter was an important period for Xspray Pharma, marked by continued regulatory clarity, disciplined financial management and further strengthening of the clinical and commercial rationale for our two lead product candidates, Dasynoc and Nilopki. While the quarter included a further regulatory delay for Dasynoc, our overall position has continued to develop in a constructive way. We have clarified the remaining regulatory path for both Dasynoc and Nilopki, continued to advance the activities required for resubmission of both NDAs, maintained our commercial readiness. After the end of the period, we were informed that the FDA had initiated a follow-up inspection at NerPharMa’s manufacturing facility, relating to previously identified cGMP-observations. The inspection is an important step in the ongoing regulatory processes for Dasynoc and Nilopki. We have also presented financing solutions aimed at securing funding through to the expected approvals of our two lead candidates.

Our strategic objective remains unchanged: to bring improved formulations of well-established and widely used oncology medicines to patients and to build Xspray into a commercial-stage oncology company. Dasynoc and Nilopki are the first two products in this strategy, each addressing distinct treatment needs within chronic myeloid leukemia, CML, where there is an established treatment market, a concentrated specialist prescriber base and clear clinical needs related to tolerability, exposure predictability, drug interactions, practical use over long treatment durations and better quality of life aspects for the patients.

Regulatory progress and path to resubmission
Dasynoc remains our near-term priority. During the quarter, Xspray received a Complete Response Letter from the FDA for Dasynoc. The FDA did not raise questions regarding the clinical data, bioequivalence or stability, and the risk of medication error raised in previous review cycles has thus been resolved. We have addressed this question over several review cycles through adjusted tablet strengths and labeling comprehension work, and we are pleased to have it closed. The remaining issues concern supporting batch data and the cGMP status of NerPharMa.

We have continued to work systematically to address the remaining requirements. For both Dasynoc and Nilopki, the required work to manufacture additional consecutive commercial-scale batch data and the related analytical work is underway. For Nilopki, we are also preparing the documentation required to establish dose correspondence with Tasigna at the relevant dose level for a defined patient sub-population.

Following dialogue with the FDA, we have confirmed that resubmission of the NDAs for Dasynoc and Nilopki may occur independently of the cGMP status of NerPharMa. It means that the timing of our resubmissions is in our own hands. At the same time, final FDA clearance of the manufacturing facility remains necessary before either product can be approved.

Our current assessment is that the Xspray-controlled activities required for resubmission of both NDAs can be completed in time to support resubmission during the fourth quarter of 2026. We therefore reiterate our plan to resubmit both applications in Q4 2026.

The NerPharMa situation remains outside Xspray’s direct control, but we are encouraged by the progress reported by the facility. NerPharMa has previously informed the FDA that it considers its facility ready for inspection. On 5 November, we were informed that the FDA had initiated an unannounced follow-up inspection at the facility. Subject to successful resubmission, FDA review and resolution of the remaining manufacturing facility matters, our plan is to be in a position to launch both Dasynoc and Nilopki in the quarter immediately following approval.

Increasing KOL Endorsement Further Supports the Long-Term Value Proposition of Xspray´s Differentiated Platform
After the end of the quarter, we held an Investor Update in Gothenburg in connection with the ESH-iCMLf John Goldman Conference on Chronic Myeloid Leukemia. The event provided an important opportunity to place our regulatory, clinical and commercial strategy in a broader scientific context with leading CML prescribers world-wide.

At the Goldman Conference, Xspray presented two scientific posters relating to Dasynoc and Nilopki. The data support our view that HyNap-formulated products can address clinically relevant limitations of established TKI therapies. For Dasynoc, the new data further support the potential importance of lower exposure variability and the future opportunity to evaluate a lower-dose dasatinib strategy. For Nilopki, the data support the potential relevance of reducing food-related exposure effects and thereby improving predictability in everyday use.
Equally important is the work of preparing the ground for our products ahead of launch. At the Goldman Conference, our two posters generated substantial discussion and feedback from physicians treating CML. That dialogue is consistent with what our earlier U.S. market research has indicated: that physicians and patients see real value in our TKI formulations offering more predictable exposure and simpler everyday use.

The Investor Update also featured Professor Michael J. Mauro and Professor Jorge Cortes, two internationally recognized CML experts and co-authors of the poster abstracts, who joined our Chief Scientific Officer Per Andersson in a moderated expert discussion. Their participation underlined the clinical relevance of the questions addressed by our science: dose, exposure variability, pleural effusion risk, food effect, cardiovascular safety considerations and patient quality of life, through our improved formulations for long-term CML treatment.

This matters because the Xspray case is not only about reaching the next regulatory milestone. Approval remains the most important near-term value driver, but the long-term opportunity is broader. The new data strengthen our belief that Dasynoc and Nilopki may offer clinically meaningful differentiation in CML and that our HyNap technology can serve as a platform for developing improved versions of established oncology medicines.

Financing and shareholder support
In connection with this report, we have announced a financing package consisting of a rights issue and an over-allotment issue. The financing has received strong support from existing shareholders and new well-reputed investors, with subscription commitments and indications corresponding to approximately 116 percent of the rights issue. The existing loan conditions have been renegotiated into a loan facility of SEK 50 million and extended to 15 August 2028.

The purpose of the financing is aligned with our previously communicated priorities: to focus resources on value-creating milestones to support the ongoing regulatory, manufacturing and pre-commercialization of Dasynoc and Nilopki, as well as to advance the company´s development pipeline and enhance its future manufacturing capacity.

We are grateful for the continued confidence shown by our shareholders and by new investors. Their support is important as we move through the final regulatory steps and prepare the company for commercial launch.

Financial discipline and efficient execution
We continue to manage Xspray’s resources with a clear focus on value creation, launch readiness and financial discipline. During the first nine months of 2026, operating expenses decreased by 15 percent compared with the corresponding period last year. In the third quarter, cash flow from operating and investing activities improved to SEK -39.0 million, compared with SEK -47.3 million in the second quarter 2026, corresponding to a 17 percent reduction in negative cash flow.

During the quarter, we also completed a contractual repayment of SEK 50.4 million of our outstanding debt financing, reducing the Company’s outstanding debt.

These measures reflect our continued commitment to responsible financial management. We are maintaining a lean and efficient organization, while preserving the capabilities required to complete the remaining regulatory work, sustain launch readiness and continue building the scientific and commercial foundation for Dasynoc, Nilopki and the broader HyNap platform.

Positioned for the next phase
Xspray is approaching a decisive phase. The regulatory process has taken longer than expected, and we recognize the patience required from shareholders and other stakeholders. At the same time, the market potential remains unchanged. CML remains a long-duration treatment setting, physicians continue to need effective and practical therapies, and the case for improved formulations of established TKIs has continued to strengthen.

Our priorities are clear: complete the remaining work required for resubmission of Dasynoc and Nilopki in the fourth quarter, closely monitoring the resolution of the NerPharMa facility matter, maintain launch readiness, secure the financing required for execution and continue building the scientific evidence behind our differentiated product profiles.

We remain focused, realistic and forward-looking. With two lead product candidates in CML, a proprietary formulation platform, a growing body of scientific evidence and continued support from shareholders and investors, we believe Xspray is well positioned to move from late-stage regulatory execution toward commercial oncology launch.

(Press release, Xspray, NOV 6, 2026, View Source [SID1234674408])

Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting

On November 6, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported it will present data on the novel mechanism of action for CTX-10726 at the 41st Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting. CTX-10726 is currently in a Phase 1 dose-escalation study in patients in the post-checkpoint setting with multiple types of advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data highlights from the presentation include:

Novel PD-1 Cleavage Mechanism. In addition to the expected dual blockade of VEGF-A and PD-1, preclinical studies also revealed a novel mechanism of action for CTX-10726. Specifically, the multimerization of CTX-10726 facilitates the cleavage and removal of PD-1 from the surface of T cells, converting PD-1 positive T cells into PD-1 negative T cells and extending the mechanism beyond simply checkpoint blockade and angiogenesis inhibition.
VEGF-A Enhanced Potency. Adding VEGF-A increased the potency of CTX-10726 approximately ten-fold in a human immune-cell assay measuring interferon-gamma production, reducing the EC50 from 2.0 to 0.2 nM. In vitro studies showed PD-1 receptor cleavage by CTX-10726 in the presence of VEGF-A compared to PD-1 receptor internalization in the absence of VEGF-A. Neither pembrolizumab nor bevacizumab alone demonstrate comparable PD-1 cleavage. Two in vivo models further demonstrated the VEGF-A-dependent nature of PD-1 receptor cleavage by CTX-10726.
Combined Activity with CTX-471. A mouse surrogate of CTX-10726 combined with CTX-471 (CD137 agonist antibody) further enhanced anti-tumor activity in mouse models, accompanied by coordinated upregulation of chemokines, interferon-stimulated genes, and inflammatory cytokines. These changes were associated with increased immune cell recruitment and establishment of a more permissive tumor microenvironment.

"These data reveal a new and differentiated mechanism of action for CTX-10726, setting it apart in this exciting new class of therapeutics," said Thomas Schuetz, MD, PhD, Chief Executive Officer. "We believe PD-1 receptor cleavage results in more potent and potentially more durable checkpoint inhibition, which supports and explains what we saw in our earlier studies. The dependence of this mechanism on VEGF links a traditionally anti-angiogenic agent directly to checkpoint control and may enhance the activity of CTX-10726 within VEGF-A-rich tumor microenvironments. We are also encouraged by the combination results with CTX-471 in checkpoint-resistant models, supporting further investigation of these complementary approaches."

The Phase 1 multiple ascending dose-escalation study of CTX-10726 includes four dosing cohorts (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 format. The multi-center study is enrolling post-checkpoint patients with a prioritized set of locally advanced, unresectable or metastatic malignancies, including renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, and endometrial cancer, in whom standard of care therapies have failed.

Details of the presentation are as follows:

Title: VEGF-dependent cleavage of cell surface PD-1 mediated by CTX-10726, a novel PD-1×VEGF-A bispecific antibody
Date & Time: Saturday, November 7, 2026 from 10:00 AM–2:00 MT PM and 6:00–8:10 MT PM
Poster number: 678
Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4-5

A copy of the presentation materials can be accessed on the Compass website at View Source once the presentation has concluded.

About CTX-10726
CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, potentially applicable to multiple solid tumor indications. The bispecific antibody demonstrates a highly stable structure with high affinity target binding. CTX-10726 exhibits more potent PD-1 suppression and a novel mechanism of action compared with data reported for other drugs in the class.

(Press release, Compass Therapeutics, NOV 6, 2026, View Source [SID1234674424])

Immunocore reports third quarter financial results and provides a business update

On November 6, 2026 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported its financial results for the third quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients," said Bahija Jallal, CEO of Immunocore. "Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes."

Third Quarter Highlights (including post-period)

Financial Results

For the third quarter ended September 30, 2026, total net product revenue (or ‘net sales’) arising from the sales of KIMMTRAK was $102.2 million, compared to $103.7 million for the same period in 2025. Q3 2026 sales were $62.2 million in the United States, $34.9 million in Europe, and $5.1 million in international regions. Revenue from net product sales compared to Q3 of 2025 was impacted by (i) United States wholesaler stocking that occurred in Q2 of 2026 and (ii) one additional week of sales in the U.S. in Q3 2025. Normalizing for the two US-related items above, underlying revenue growth for this quarter was approximately 10%, as compared to Q3 2025.

For the nine months ended September 30, 2026, net sales of KIMMTRAK were $324.8 million, compared to $295.5 million for the same period in 2025. For the nine months ended September 30, 2026, sales were $204.6 million in the United States, $103.5 million in Europe and $16.7 million in international regions. The increase in net product sales was due to continued growth in the United States, Europe and international regions.

Research and development (R&D) expenses for Q3 2026 were $74.7 million, compared to $70.6 million for Q3 2025. This increase was primarily due to advancement of our clinical programs, including our three Phase 3 trials.

Selling, general and administrative (SG&A) expenses for Q3 2026 were $40.5 million, compared to $39.8 million for Q3 2025.

Net loss for Q3 2026 was $14.2 million ($0.28 loss per share) compared to $0.2 million ($0.00 loss per share) for Q3 2025. Net loss for the nine months ended September 30, 2026, was $2.1 million ($0.04 loss per share) compared to $5.5 million ($0.11 loss per share) for the nine months ended September 30, 2025.

Cash, cash equivalents and marketable securities were $901.3 million as of September 30, 2026, as compared to $864.2 million as of December 31, 2025. The Company expects to pay, in the fourth quarter of 2026, approximately $120 million in sales-related rebate accruals.

KIMMTRAK

The Company’s lead product, KIMMTRAK, is approved in 39 countries and has been launched in over 30 countries globally to date for HLA-A*02:01 positive people with unresectable or metastatic uveal melanoma (mUM). KIMMTRAK continues to be the standard of care in all major markets where it is launched.

The Company sees three key growth areas for KIMMTRAK as it plans to expand patient reach, including continued US community and global market penetration in mUM, the potential expansion into 2L+ advanced cutaneous melanoma (CM), and the potential expansion into adjuvant uveal melanoma.

Metastatic uveal melanoma

The five-year overall survival (OS) data from the Phase 3 trial of KIMMTRAK in patients with unresectable or mUM, which were presented at the AACR (Free AACR Whitepaper) 2026 meeting, have been accepted by the European Medicines Agency for inclusion in the European SmPC (Summary of Product Characteristics). This addition to the SmPC will allow the Company to engage more broadly with healthcare professionals in the region about the data.
The Company received the International Prix Galien 2026 for KIMMTRAK in the orphan/rare diseases category. This is the fifth Prix Galien awarded to KIMMTRAK.

2L+ advanced cutaneous melanoma

The registrational Phase 3 TEBE-AM trial, evaluating tebentafusp as monotherapy and in combination with pembrolizumab, versus a control arm in patients with previously treated advanced CM, has achieved its target enrollment of 540 patients. The trial is event-driven and topline overall survival data is expected in the second quarter of 2027.
There is great unmet need in second- and later-line CM, with no therapy, to date, having shown an OS improvement following progression on checkpoint inhibitors in a randomized clinical trial. The Company estimates there are up to 4,000 HLA-A*02:01 positive, previously treated, advanced CM patients in the US and Europe.
Adjuvant uveal (or ocular) melanoma

The European Organisation for Research and Treatment of Cancer (EORTC) is enrolling patients in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM) in Europe and the United States.
The Company estimates the HLA-A*02:01 positive, high-risk adjuvant uveal melanoma patient population could represent up to 1,200 patients in the US and Europe.
PRAME portfolio

Brenetafusp is the Company’s lead PRAME-A02 ImmTAC bispecific candidate. Brenetafusp is being evaluated in combination with nivolumab in a Phase 3 registrational trial (PRISM-MEL-301) in patients with first-line, advanced cutaneous melanoma, and in a Phase 1/2 clinical trial as monotherapy and in combination across multiple solid tumors, including ovarian cancer, uveal melanoma, and non-small cell lung cancer (NSCLC).

PRISM-MEL-301 – First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma

The Company continues enrollment of HLA-A*02:01 positive, first-line, advanced or metastatic cutaneous melanoma patients with 1:1 randomization to brenetafusp 160 mcg + nivolumab or a control arm of either nivolumab or nivolumab + relatlimab.
Despite approved therapies, there remains an unmet need for improved progression-free survival and OS in the first-line setting, where there is the potential to address an estimated 10,000 HLA-A*02:01 positive patients across the US and Europe.
Phase 1/2 clinical trials of brenetafusp and IMC-P115C (PRAME-A02 Half-Life Extended) in multiple solid tumors

Combination of KIMMTRAK and brenetafusp in metastatic uveal melanoma

As of June 2026, 22 HLA-A*02:01 positive adult patients with mUM received brenetafusp monotherapy at clinically active doses and 26 received the combination of KIMMTRAK and brenetafusp.
Among the 16 evaluable patients who received brenetafusp monotherapy in the second-line or later setting, overall response rate (ORR) was 19%, median duration of response (mDoR) was 14.5 months, median progression-free survival (mPFS) was 4.2 months, and median OS was 20.3 months.
Across the 17 evaluable first-line patients who received the combination, ORR was 29%, mDoR was 24.1 months, mPFS was 8.1 months, and median OS was not yet reached with 29 months of follow-up and 10 patients still on study. The two-year OS rate was 70%.
The most common brenetafusp monotherapy treatment-related adverse events (TRAEs) were reversible and manageable cytokine release syndrome (CRS) (73%) and rash (50%) consistent with the molecule’s mechanism of action. Grade 3/4 TRAEs were primarily transient lymphocyte decrease which resolved without intervention.
Combination regimens were generally well-tolerated. The most common TRAEs were Grade 1/2 CRS and rash (77% each). These attenuated over time with no Grade ≥3 CRS reported. No TRAE led to discontinuation or death.
The Company will present these data in a poster today at 10:00 a.m. MST / 12:00 p.m. ET and in an oral session, Saturday, November 7 at 1:45 p.m. MST / 3:45 p.m. ET, at the 2026 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting.
The Company believes these are the first data showing clinical activity and a manageable safety profile for a combination of two T cell engagers in a solid tumor.
Based on these data, the Company is planning to start DUET-UVEAL, a randomized Phase 2/3 trial, to evaluate the combination for the treatment of HLA-A*02:01-positive patients with mUM.
Brenetafusp in other tumors and IMC-P115C

After observing an initial brenetafusp monotherapy signal in platinum-resistant ovarian cancer (PROC), the Company is evaluating, as part of an ongoing Phase 1/2 trial, combination therapy with bevacizumab in earlier lines, including platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection across multiple metastatic non-small cell lung cancer (NSCLC) cohorts, including combinations with standards of care in earlier-line NSCLC.
The Company expects to present clinical data for brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year.
In parallel, the Company is continuing to enroll patients in the Phase 1 dose escalation trial evaluating IMC-P115C in patients with multiple solid tumors.

ImmTAV candidates for a functional cure in infectious diseases

The Company’s bispecific TCR technology platform has the potential to offer a new approach for the treatment of certain chronic infections by eliminating the remaining virus in circulation after the patients stop taking their antiviral medication – known as a ‘functional cure’. The Company is studying an investigational candidate for people living with human immunodeficiency virus (HIV).

Phase 1/2 trial of IMC-M113V (Gag-A02) for people living with HIV

In July 2026, at the International AIDS Society meeting in Rio de Janeiro, the Company presented translational data, from the first three cohorts of the multiple ascending dose (MAD) part of the Phase 1/2 trial, demonstrating that IMC-M113V induces robust type I and II interferon-associated immune programs, with stronger induction in participants who maintained viral control after treatment interruption.
The data also showed that, in addition to previously demonstrated direct killing of HIV-infected cells, IMC-M113V redirection of T cells results in induction of a robust interferon-associated immune program that may contribute to post-treatment viral control.
The Company completed enrollment of additional patients at higher dose cohorts, up to 1200 mcg, as part of the MAD portion of the Phase 1/2 trial. Analysis of the new data is ongoing with results planned to be shared early next year.

Tissue-specific down modulation of the immune system for autoimmune diseases
The key differentiator of the ImmTAAI platform is down modulation of the immune system in a tissue-specific manner. The candidates achieve this by suppressing pathogenic T cells via PD1 receptor agonism only when tethered to the target tissue.

The Company recently announced that the first person with type 1 diabetes has been dosed in the Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate.
IMC-S118AI is designed to bind preproinsulin on beta cells of the pancreas and deliver a PD-1 agonist signal to nearby auto-reactive T cells, thereby protecting the pancreatic beta cells from T cell attack, preserving beta cell mass, and avoiding systemic immune suppression.
The Company plans to file a clinical trial application (CTA) or investigational new drug (IND) application before the end of the year for its second autoimmune program, IMC-U120AI (CD1a x PD1), which is designed to target a variety of dermatological diseases including atopic dermatitis.

(Press release, Immunocore, NOV 6, 2026, View Source [SID1234674391])

OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026

On November 4, 2026 OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological and immunological diseases, reported encouraging Phase 1/2 results for cesalatamig (AI-081), its investigational PD-1/VEGF bispecific antibody, as monotherapy in patients with PD-(L)1-resistant/refractory non-small cell lung cancer (NSCLC). The findings will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results reported in the SITC (Free SITC Whitepaper) abstract were derived from a pooled analysis of the global, multicenter, open-label BiPAVE-001 and BiPAVE-001 CN Phase 1/2 studies. As of July 31, 2026, the safety population included 103 patients with NSCLC who had received at least one dose of cesalatamig monotherapy at 1, 3, 10 or 20 mg/kg Q3W. Of these patients, 77 (75%) had non-squamous histology, 25 (24%) had squamous histology and one had unknown histology. 77% of patients had a baseline ECOG performance status of 1. The median number of prior therapy lines was two, and 42% of patients had received three or more prior lines. The safety profile was comparable between patients with squamous and non-squamous histology. The cesalatamig monotherapy is well tolerated at all dose levels.

Among 55 efficacy-evaluable patients with PD-(L)1 resistant/refractory NSCLC, cesalatamig monotherapy demonstrated dose-dependent antitumor activity. At 1 mg/kg (10 patients), 3 mg/kg (24 patients) and 10 mg/kg (21 patients) Q3W, investigator-assessed objective response rates (ORR) were 10%, 21% and 33%, respectively; disease control rates (DCR) were 40%, 67% and 90%, respectively. Responses to cesalatamig monotherapy were observed across PD-L1 expression levels. Exposure-response analyses support selection of 10 mg/kg Q3W as the dose for further development.

"Patients whose NSCLC progresses after immunotherapy and chemotherapy have limited effective treatment options," said Kai He, MD, PhD, principal investigator of the US BiPAVE-001 trial and the presenter of this study. "The responses and disease control observed with cesalatamig monotherapy are encouraging. Together with the manageable safety profile observed in these studies, these findings support further clinical evaluation in this setting."

"These findings strengthen the rationale for advancing cesalatamig monotherapy in previously treated NSCLC," said Yang Liu, PhD, Co-founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. "The clinical results and exposure-response analyses support the selection of 10 mg/kg every three weeks as the dose for our planned pivotal study and provide a clear path forward for the continued development of cesalatamig in this setting."

Presentation Information

Title: Safety and Efficacy of Cesalatamig, a Novel PD-1/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1–Resistant/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1/2 Studies

Abstract: #1187 (late-breaking oral presentation)
Presenter: Kai He, MD, PhD
Date: November 7, 2026
Meeting: 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), Phoenix, Arizona
Session: Clinical Oral Abstract Session 2, beginning at 1:45 PM MST

About Cesalatamig

Cesalatamig (AI-081) is an investigational, tetravalent PD-1/VEGF bispecific antibody designed to promote cooperative interactions between PD-1 and VEGF blockade in the tumor microenvironment. It combines high-affinity binding with Fc-silencing modifications intended to avoid depletion of PD-1-positive effector T cells. Cesalatamig is being evaluated as monotherapy and in combination with standard of care in the ongoing BiPAVE-001 clinical program. In September 2026, the U.S. FDA granted cesalatamig Fast Track designation for NSCLC that has progressed after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.

About BiPAVE-001

BiPAVE-001 (NCT06635785) and BiPAVE-001 CN (CTR20253261) are ongoing Phase 1/2 clinical trials evaluating the safety, pharmacokinetics, and efficacy of cesalatamig (AI-081), a bispecific antibody targeting PD-1 and VEGF, in patients with advanced solid tumors. OncoC4 is conducting these studies in the United States and China, respectively. Part A is the first-in-human Phase 1 dose-escalation and dose-expansion portion in patients with advanced solid tumors. Part B is the Phase 2 portion and includes dose-optimization trials evaluating AI-081 as monotherapy or in combination with standard of care in selected indications.

(Press release, OncoC4, NOV 6, 2026, View Source [SID1234674409])